


[EBMT](#)

[Annual report](#)

[2024](#)



[ScienceEducationPatient Care & Advocacy](#)

[Our SocietyOur Mission, Vision & ValuesEBMT Membership 2024Organisational Structure 2024Financial Highlights 2024EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Ali Bazarbachi

LWP Chair (ELECTED APRIL 2024, PREVIOUS CHAIR: Bertram Glass)

Lebanon

Major achievements

The new board of the Lymphoma Working Party has been designated after the 2024 Annual Meeting in Glasgow. The transition had been officialised in Paris on June 5, 2024. The elected chair Ali Bazarbachi has chosen to work with two secretaries: Charalampia Kyriakou as secretary for the first two years with Yasmina Serroukh as vice-secretary. It has been agreed that these roles will be switched after two years.

The first innovation of the new board has been the introduction of **sub-committees** (with two co-leaders for each) with the following topics:


- *Mantle cell lymphoma* (Olivier Hermine and Peter Dreger)
- *Large B cell lymphoma* (Catherine Thieblemont and Bertram Glass)
- *Immunotherapy and CAR T cells* (Anna Ossami Saidy and Remy Dulery)
- *Hodgkin* (Anna Sureda and Alina Tanase)
- *T cell lymphoma* (Norbert Schmitz and Ghandi Damaj)
- *Indolent B cell lymphoma* (Silvia Montoto and Luca Castagna)
- *Waldenstrom's macroglobulinemia* (Nour Moukalled and Charalampia Kyriakou)

Each subcommittee meets online every three months with LWP members, study coordinators and statisticians to discuss the progress of ongoing projects and approve new projects. All EBMT members are welcome to attend. In addition to these frequent one-hour meetings, the lymphoma working party members meet in person twice a year: at the Annual Meeting in the spring and at the educational meeting in the fall.



Lymphoma Working Party Educational Course - Rotterdam, The Netherlands - 30 Oct. - 1 Nov. 2024

This way of working has immediately dynamized the productivity which resulted in a large number of poster and oral presentations at ASH 2024 (see the [news article](#)). These abstracts will hopefully lead to publications in 2025, as will the other ongoing projects in the writing and submission phases.



Principal research studies

[OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST TRANSPLANT AFTER CHECKPOINT INHIBITORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Hodgkin's Disease \(HD\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Carmen Martínez](#)

[Efficacy and toxicity of CAR T cell therapy in patients with primary and secondary central nervous system lymphoma](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[GoCART Coalition](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Anna Ossami Saidy](#)

[Autologous Hematopoietic Stem Cell Transplantation for Natural Killer/T-cell](#)

[Lymphoma as Consolidation and Relapse Treatment](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Philipp Berning](#)

[Allogeneic stem cell transplantation for Follicular lymphoma, a benchmark study of](#)

[the Lymphoma Working Party](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Non-Hodgkin's Lymphoma \(NHL\)](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Yasmina Serroukh](#)

Key publications

2024

Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor

Group

Lymphoma Working Party (LWP)

1st listed author

Annalisa Paviglianiti

Journal

Bone Marrow Transplant.

2024

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Group

Lymphoma Working Party (LWP)

1st listed author

Juan Montoro

Journal

Transplant Cell Ther.

2024

Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years

Group

Lymphoma Working Party (LWP)

1st listed author

Philipp Berning

Journal

Blood Cancer J.

2024

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study

Group

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Simon Renders](#)

[Journal](#)

[Blood Adv.](#)

[2024](#)

[PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Juan Montoro](#)

[Journal](#)


[Blood Adv.](#)

[See the full list of the LWP 2024 publications](#)




Indicators

Impact factor (Lymphoma)



2022 2023 2024

Oral presentations	2	10	10
Poster presentations	3	5	7
Educational events	1	1	2



[Event](#)

50th Annual Meeting of the EBMT



[Kingdom](#)

[Event](#)

Lymphoma Working Party Educational Course 2024

[Oct 30, 2024 - Nov 01, 2024 / Rotterdam, Netherlands](#)

[Discover more](#)

[VISIT THE LWP WEBPAGE](#)